Strategic Acquisition Evergreen Theragnostics was acquired by Lantheus in 2025 for $250 million, positioning it within a larger radiopharmaceutical ecosystem and indicating potential for collaborative opportunities, licensing, or joint ventures with parent company Lantheus.

Growing Market Presence With recent partnerships with Jubilant Radiopharma and RLS (USA) Inc. to distribute OCTEVY and expand therapeutic options, Evergreen is actively increasing its market reach and distribution network, presenting opportunities for sales expansion in the radiopharmaceutical and PET imaging sectors.

Innovation & Supply Chain The launch of a new discovery unit and the preparation of Ga-68 DOTATOC supply chain demonstrate Evergreen’s focus on developing innovative radiopharmaceutical products, providing opportunities to offer complementary technologies, supply chain solutions, or related components.

Funding & Growth Having secured $26 million in recent funding, along with a revenue range of $25 million to $50 million, Evergreen shows strong growth potential that can be leveraged to introduce new products, expand production capabilities, and target emerging market segments.

Industry Positioning As a specialized radiopharmaceutical CDMO with deep expertise and a focus on theranostics, Evergreen possesses a niche positioning that opens sales opportunities with biotech, pharma, and healthcare organizations seeking high-quality manufacturing and development partners in this growing field.